Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Upcoming events – Fibroid data for Obseva, as Inventiva turns to Nash
EP Vantage
Fri, 03/6/20 - 10:49 am
ObsEva
uterine fibroids
clinical trials
NASH
Inventiva
lanifibranor
Novo bids for recognition in the year of NASH
EP Vantage
Thu, 03/5/20 - 10:39 am
NASH
Novo Nordisk
Ozempic
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data
Xconomy
Tue, 02/25/20 - 12:04 am
NGM Biopharmaceuticals
NASH
clinical trials
aldafermin
Genfit's NASH key phase 3 data delayed
Fierce Biotech
Fri, 02/21/20 - 10:32 am
Genfit
NASH
clinical trials
elafibranor
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Sat, 01/18/20 - 07:34 pm
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
While expected, Intercept's approval delay adds to NASH uncertainty
BioPharma Dive
Sat, 01/18/20 - 07:33 pm
Intercept Pharma
NASH
FDA
obeticholic acid
#JPM20: After Year of NASH collapses, all eyes on two biotechs
Endpoints
Thu, 01/16/20 - 10:14 am
NASH
JPMHC 20
Genfit
Gilead Sciences
Fish oil pill for NASH? Dutch biotech scores $40M injection to make a mark in the bustling field
Endpoints
Wed, 01/8/20 - 10:41 am
NASH
NorthSea Therapeutics
Amarin
Cirius withdraws $86M IPO as vaunted 'Year of NASH' draws to brutal close
Endpoints
Mon, 12/23/19 - 11:50 pm
Cirius Therapeutics
NASH
Will we see the world's first approved NASH drug in 2020?
Fierce Biotech
Fri, 12/20/19 - 10:20 am
NASH
Intercept Pharma
Genfit
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Intercept's NASH decision delayed by FDA, but don't panic: analysts
Fierce Pharma
Mon, 12/16/19 - 10:31 am
Intercept Pharmaceuticals
NASH
obeticholic acid
FDA
2 NASH drugmakers have wildly different Mondays
Biopharma Dive
Mon, 11/25/19 - 10:11 pm
Intercept Pharmaceuticals
CymaBay Therapeutics
FDA
NASH
seladelpar
obeticholic acid
Poxel taking two shots at NASH as pharma waits on FDA’s Ocaliva verdict
Pharmaforum
Wed, 11/20/19 - 10:17 pm
Intercept Pharma
Poxel
NASH
Ocaliva
PXL065
PXL770
Intercept aims to triple sales force as it gears up for potential NASH launch
Fierce Pharma
Thu, 11/14/19 - 07:42 pm
Intercept Pharma
hirings
drug reps
NASH
drug launches
Ocaliva
obeticholic acid
Genfit trumpets new NASH blood biopsy data
Pharmaforum
Tue, 11/12/19 - 08:01 pm
Genfit
NASH
diagnostics
liquid biopsy
AASLD: Gilead wants to move the needle for fatty liver therapies
Fierce Biotech
Mon, 11/11/19 - 10:46 am
Gilead Sciences
NASH
selonsertib
clinical trials
AASLD
Novo Nordisk buys rights to NASH drug from Japan’s UBE
Pharmaforum
Fri, 11/8/19 - 10:49 am
Novo Nordisk
NASH
Japan
UBE
UD-014
FDA grants fast track status to Terns’s FXR agonist to treat NASH
Pharmaceutical Business Review
Wed, 10/30/19 - 10:01 am
Terns Pharmaceuticals
FDA
NASH
TERN-101
fast track
What to make of Gilead's latest NASH deal
Biopharma Dive
Mon, 10/28/19 - 11:04 pm
Gilead Sciences
Glympse Bio
biomarkers
NASH
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »